Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An agestratified analysis.

被引：0
|
作者：
Vassilev, Zdravko
Fan, Xiaozhou
Ostojic, Helene
Xu, Julie
Barzi, Afsaneh
机构：
[1] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[2] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
64
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [1] Front-line use of FOLFOXIRI plus bevacizumab and subsequent therapies in metastatic colorectal cancer (mCRC).
    Barzi, Afsaneh
    Lunacsek, Orsolya
    Pisa, Federica
    Pan, Xiaoyun
    Ostojic, Helene
    Vassilev, Zdravko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 45 - 45
  • [2] FOLFOXIRI plus Bevacizumab in metastatic colorectal Cancer
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07): : 630 - 630
  • [3] Use of FOLFOXIRI Plus Bevacizumab and Subsequent Therapies in Metastatic Colorectal Cancer: An Age-Stratified Analysis
    Vassilev, Zdravko P.
    Fan, Xiaozhou
    Xu, Julie
    Ostojic, Helene
    Barzi, Afsaneh
    CLINICAL COLORECTAL CANCER, 2024, 23 (03)
  • [4] FOLFOXIRI and bevacizumab in metastatic colorectal cancer
    Rahman, Ahmadur
    LANCET ONCOLOGY, 2014, 15 (13): : E590 - E590
  • [5] FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
    Haines, Ian E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (03): : 290 - 291
  • [6] FOLFOXIRI Plus Bevacizumab Versus FOLFOX/FOLFIRI Plus Bevacizumab for Metastatic Colorectal Cancer: An Updated Meta-Analysis
    Muhibullah, Fnu
    Shafique, Nouman
    Khakwani, Anum
    Qadeer, Abdul
    Bajwa, Shammas Farooq
    Ehsan, Amna
    Aiman, Wajeeha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S175 - S176
  • [7] Efficacy of FOLFOXIRI versus XELOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer
    Cheng, Yuzhuo
    Song, Weiliang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (10): : 18713 - 18720
  • [8] Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
    Bond, Marinde J. G.
    van Smeden, Maarten
    Degeling, Koen
    Cremolini, Chiara
    Schmoll, Hans-Joachim
    Antoniotti, Carlotta
    Lonardi, Sara
    Murgioni, Sabina
    Rossini, Daniele
    Ibach, Stefan
    Koopman, Miriam
    Swijnenburg, Rutger-Jan
    Punt, Cornelis J. A.
    May, Anne M.
    Kwakman, Johannes J. M.
    JCO CLINICAL CANCER INFORMATICS, 2024, 8
  • [9] Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
    Bond, Marinde J. G.
    van Smeden, Maarten
    Degeling, Koen
    Cremolini, Chiara
    Schmoll, Hans-Joachim
    Antoniotti, Carlotta
    Lonardi, Sara
    Murgioni, Sabina
    Rossini, Daniele
    Ibach, Stefan
    Koopman, Miriam
    Swijnenburg, Rutger-Jan
    Punt, Cornelis J. A.
    May, Anne M.
    Kwakman, Johannes J. M.
    JCO CLINICAL CANCER INFORMATICS, 2024, 8
  • [10] Intensified First Line Therapy of the metastatic colorectal Cancer with FOLFOXIRI plus Bevacizumab
    Ruessel, J.
    ONKOLOGE, 2015, 21 (04): : 334 - 335
12345